NASDAQ:ALKS Alkermes - ALKS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Alkermes plc Please log in to your account or sign up in order to add this asset to your watchlist. $28.50 +0.16 (+0.56%) (As of 01/26/2023 12:00 AM ET) Add Compare Share Share Today's Range$28.16▼$28.5550-Day Range$23.44▼$28.5452-Week Range$21.75▼$32.79Volume1.04 million shsAverage Volume1.54 million shsMarket Capitalization$4.68 billionP/E RatioN/ADividend YieldN/APrice Target$30.10 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Alkermes MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside4.9% Upside$29.89 Price TargetShort InterestBearish5.70% of Shares Sold ShortDividend StrengthN/ASustainability-1.22Upright™ Environmental ScoreNews Sentiment0.30Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.29) to ($0.21) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.44 out of 5 starsMedical Sector970th out of 1,048 stocksPharmaceutical Preparations Industry471st out of 513 stocks 1.2 Analyst's Opinion Consensus RatingAlkermes has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 3 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $29.89, Alkermes has a forecasted upside of 4.9% from its current price of $28.50.Amount of Analyst CoverageAlkermes has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.70% of the outstanding shares of Alkermes have been sold short.Short Interest Ratio / Days to CoverAlkermes has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Alkermes has recently increased by 1.85%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAlkermes does not currently pay a dividend.Dividend GrowthAlkermes does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAlkermes has received a 69.44% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is mostly driven by its "Antipsychotics", "Naltrexone", and "Clinical research services for mental health" products. See details.Environmental SustainabilityThe Environmental Impact score for Alkermes is -1.22. Previous Next 2.4 News and Social Media Coverage News SentimentAlkermes has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Alkermes this week, compared to 6 articles on an average week.Search Interest8 people have searched for ALKS on MarketBeat in the last 30 days. MarketBeat FollowsOnly 2 people have added Alkermes to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alkermes insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.76% of the stock of Alkermes is held by insiders.Percentage Held by Institutions96.15% of the stock of Alkermes is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Alkermes are expected to grow in the coming year, from ($0.29) to ($0.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alkermes is -36.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alkermes is -36.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlkermes has a P/B Ratio of 4.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Alkermes (NASDAQ:ALKS) StockAlkermes Plc is a global biopharmaceutical company. It is engaged in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.Read More Receive ALKS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter. Email Address ALKS Stock News HeadlinesJanuary 27, 2023 | americanbankingnews.comAlkermes plc (NASDAQ:ALKS) Forecasted to Earn FY2022 Earnings of ($0.19) Per ShareJanuary 19, 2023 | americanbankingnews.comAlkermes plc (NASDAQ:ALKS) Forecasted to Post FY2022 Earnings of ($0.25) Per ShareJanuary 27, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…January 17, 2023 | finance.yahoo.comAlkermes Awarded Innovation Passport Designation by the MHRA (UK) for Nemvaleukin Alfa for the Treatment of Mucosal MelanomaJanuary 14, 2023 | seekingalpha.comAlkermes (ALKS) Presents at the 41st Annual J.P. Morgan Healthcare Conference -- SlideshowDecember 28, 2022 | finance.yahoo.comAlkermes to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 26, 2022 | thestreet.comAlkermes Testing Schizophrenia DrugDecember 26, 2022 | thestreet.comAlkermes Depression Drug Failure Crimps Future Growth OutlookJanuary 27, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…November 30, 2022 | finance.yahoo.comAlkermes to Participate in the BofA Securities 2022 Biotech SMID Cap ConferenceNovember 22, 2022 | finance.yahoo.comAlkermes to Participate in the 5th Annual Evercore ISI HealthCONx ConferenceNovember 8, 2022 | finance.yahoo.comAlkermes to Participate in the Stifel Healthcare ConferenceNovember 7, 2022 | finance.yahoo.comAlkermes Announces Recipients of 2022 Alkermes Inspiration Grants(R) ProgramOctober 27, 2022 | finance.yahoo.comAlkermes Announces Recipients of 2022 Alkermes Inspiration Grants® ProgramOctober 26, 2022 | finance.yahoo.comAlkermes to Report Third Quarter Financial Results on Nov. 2, 2022October 17, 2022 | seekingalpha.comACOR stock gains after winning $16.5M from Alkermes in arbitration case (NASDAQ:ACOR) - Seeking AlphaOctober 17, 2022 | streetinsider.comAcorda Therapeutics (ACOR) Awarded $16.5M in Arbitration Case with Alkermes (ALKS) - StreetInsider.comOctober 17, 2022 | nasdaq.comAcorda Announces $16.5 Mln Award And Royalty/Supply Relief In AMPYRA Arbitration Case With Alkermes - NasdaqOctober 16, 2022 | businesswire.comAcorda Therapeutics Announces $16.5M Award and Royalty/Supply Relief in AMPYRA® Arbitration Case - Business WireOctober 14, 2022 | wnewsj.comBridge to past & future: Community celebrates 150 years of Champion Bridge Co. - Wilmington News Journal, OHOctober 14, 2022 | uk.investing.comDomino's Pizza To Rally 20%? Here Are 5 Other Price Target Changes For Friday By Benzinga - Investing.com UKOctober 14, 2022 | seekingalpha.comAlkermes upgraded to neutral at BofA on improved risk/reward outlook (NASDAQ:ALKS) - Seeking AlphaOctober 7, 2022 | seekingalpha.comAlkermes holder Sarissa Capital says it may look to increase its stake (NASDAQ:ALKS) - Seeking AlphaOctober 7, 2022 | streetinsider.comRectify Pharmaceuticals Appoints Robert Hughes as Executive Vice President, Drug Discovery and Preclinical Development, and Xiaobing Li as Chief Development Officer - StreetInsider.comOctober 6, 2022 | finance.yahoo.comRectify Pharmaceuticals Appoints Robert Hughes as Executive Vice President, Drug Discovery and Preclinical Development, and Xiaobing Li as Chief Development Officer - Yahoo FinanceOctober 3, 2022 | finance.yahoo.com47% of Heavy Drinkers Seek Treatment Because of a Family Member - Yahoo FinanceSeptember 29, 2022 | reuters.comALKS.O - Alkermes Plc | Stock Price & Latest News | ReutersSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ALKS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter. Email Address ALKS Company Calendar Last Earnings11/02/2022Today1/26/2023Next Earnings (Estimated)2/15/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:ALKS CUSIPG0176710 CIK1520262 Webwww.alkermes.com Phone(531) 772-8000Fax781-890-0524Employees2,211Year Founded1987Price Target and Rating Average Stock Price Forecast$29.89 High Stock Price Forecast$36.00 Low Stock Price Forecast$25.00 Forecasted Upside/Downside+5.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-48,170,000.00 Net Margins-11.41% Pretax Margin-12.85% Return on Equity-1.10% Return on Assets-0.60% Debt Debt-to-Equity Ratio0.28 Current Ratio2.24 Quick Ratio1.89 Sales & Book Value Annual Sales$1.17 billion Price / Sales3.99 Cash Flow$0.75 per share Price / Cash Flow37.98 Book Value$6.88 per share Price / Book4.14Miscellaneous Outstanding Shares164,312,000Free Float156,491,000Market Cap$4.68 billion OptionableOptionable Beta0.57 Social Links Key ExecutivesRichard F. PopsChairman & Chief Executive OfficerBlair C. JacksonChief Operating Officer & Executive Vice PresidentIain Michael BrownChief Financial Officer & Senior Vice PresidentThomas HarveyChief Information OfficerKanchan RelwaniSenior Vice President-Medical AffairsKey CompetitorsMadrigal PharmaceuticalsNASDAQ:MDGLAmicus TherapeuticsNASDAQ:FOLDIonis PharmaceuticalsNASDAQ:IONSIronwood PharmaceuticalsNASDAQ:IRWDDynavax TechnologiesNASDAQ:DVAXView All CompetitorsInsiders & InstitutionsStrs OhioSold 10,900 shares on 1/26/2023Ownership: 0.024%Dupont Capital Management CorpBought 877 shares on 1/26/2023Ownership: 0.008%Paradiem LLCBought 4,610 shares on 1/24/2023Ownership: 0.028%Xponance Inc.Bought 427 shares on 1/24/2023Ownership: 0.006%Harbor Capital Advisors Inc.Bought 27,406 shares on 1/20/2023Ownership: 0.024%View All Insider TransactionsView All Institutional Transactions ALKS Stock - Frequently Asked Questions Should I buy or sell Alkermes stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last twelve months. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ALKS shares. View ALKS analyst ratings or view top-rated stocks. What is Alkermes' stock price forecast for 2023? 8 Wall Street research analysts have issued twelve-month price objectives for Alkermes' stock. Their ALKS share price forecasts range from $25.00 to $36.00. On average, they expect the company's stock price to reach $30.10 in the next twelve months. This suggests a possible upside of 5.6% from the stock's current price. View analysts price targets for ALKS or view top-rated stocks among Wall Street analysts. How have ALKS shares performed in 2023? Alkermes' stock was trading at $26.13 at the beginning of 2023. Since then, ALKS stock has increased by 9.1% and is now trading at $28.50. View the best growth stocks for 2023 here. When is Alkermes' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 15th 2023. View our ALKS earnings forecast. How were Alkermes' earnings last quarter? Alkermes plc (NASDAQ:ALKS) issued its quarterly earnings data on Wednesday, November, 2nd. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by $0.01. The firm had revenue of $252.36 million for the quarter, compared to analyst estimates of $271.45 million. Alkermes had a negative trailing twelve-month return on equity of 1.10% and a negative net margin of 11.41%. The company's quarterly revenue was down 14.2% compared to the same quarter last year. During the same period last year, the company posted ($0.02) earnings per share. What guidance has Alkermes issued on next quarter's earnings? Alkermes issued an update on its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided earnings per share guidance of $0.15-$0.33 for the period, compared to the consensus earnings per share estimate of $0.20. The company issued revenue guidance of $1.07 billion-$1.12 billion, compared to the consensus revenue estimate of $1.10 billion. What is Richard F. Pops' approval rating as Alkermes' CEO? 119 employees have rated Alkermes Chief Executive Officer Richard F. Pops on Glassdoor.com. Richard F. Pops has an approval rating of 84% among the company's employees. What other stocks do shareholders of Alkermes own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX), Intel (INTC), Johnson & Johnson (JNJ) and Tesla (TSLA). What is Alkermes' stock symbol? Alkermes trades on the NASDAQ under the ticker symbol "ALKS." Who are Alkermes' major shareholders? Alkermes' stock is owned by many different retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.10%), Paradiem LLC (0.03%), Harbor Capital Advisors Inc. (0.02%), Strs Ohio (0.02%), Diversified Trust Co (0.02%) and Dupont Capital Management Corp (0.01%). Insiders that own company stock include Blair Curtis Jackson, Christian Todd Nichols, Craig C Hopkinson, Craig C Hopkinson, David Joseph Gaffin, David W Anstice, Emily Peterson Alva, Iain Michael Brown, Michael J Landine, Nancy Wysenski, Richard F Pops, Shane Cooke and Wendy L Dixon. View institutional ownership trends. How do I buy shares of Alkermes? Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Alkermes' stock price today? One share of ALKS stock can currently be purchased for approximately $28.50. How much money does Alkermes make? Alkermes (NASDAQ:ALKS) has a market capitalization of $4.68 billion and generates $1.17 billion in revenue each year. The company earns $-48,170,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis. How many employees does Alkermes have? The company employs 2,211 workers across the globe. Does Alkermes have any subsidiaries? The following companies are subsidiares of Alkermes: Rodin Therapeutics.Read More How can I contact Alkermes? Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The official website for the company is www.alkermes.com. The company can be reached via phone at (531) 772-8000, via email at investor_relations@alkermes.com, or via fax at 781-890-0524. This page (NASDAQ:ALKS) was last updated on 1/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.